This excess ATP switches on a receptor called P2Y2, which then recruits a partner protein called integrin β1 to form a protective barrier around the mutant EGFR. This barrier stops the faulty protein ...
Impact of lorlatinib dose modifications on adverse event outcomes in the phase 3 CROWN study. RC108 in combination with furmonertinib in patients with locally advanced or metastatic EGFR-mutated ...
Researchers from Singapore’s A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) report that they have identified why certain lung cancer cells become highly resistant to treatment after ...
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer Testing was performed ...
PBS293-MMAE targets EGFR and EphA2, two proteins shown to be co-expressed in colorectal cancer cells. While EGFR is a clinically validated target in colorectal cancer, therapeutic antibodies such as ...
Data presented at 16th World ADC London Summit with lead programme in colorectal cancer highlight the promise of Promatix’s proteomics-based ...
If you have non-small-cell lung cancer (NSCLC) with an EGFR mutation, your health care provider may recommend a new medicine called Datroway (datopotamab deruxtecan-dlnk). NSCLC is the most common ...
A proposed function of TADs is to contribute to gene regulation by promoting chromatin interactions within a TAD and by suppressing interactions between TADs. Here, we directly probe the ...
Propagation of expression noise from mRNA to protein level is influenced by variation in availability of ribosomal machinery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results